Bicara Therapeutics Inc (NAS:BCAX)
$ 29.34 +2.47 (+9.19%) Market Cap: 1.93 Bil Enterprise Value: 1.39 Bil PE Ratio: 0 PB Ratio: 3.74 GF Score: 12/100

Bicara Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 10, 2026 / 03:30 PM GMT
Release Date Price: $20.06 (+1.83%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BCAX.OQ - Bicara Therapeutics Inc
Bicara Therapeutics Inc at Barclays Global Healthcare Conference
Mar 10, 2026 / 03:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello everyone, I'm Eda Derot, senior biotech analyst at Barclays, happy to have BICAra Therapeutics, with us for our next session.

We have Ryan Coheap, President and Chief Operating Officer. Ryan, maybe for those less familiar with the story, if you could just give us an overview of BICAra and progress that you've made in upcoming milestones.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Yeah, great. Now thank you for the invitation and having us here at the conference. So Bicar Therapeutics is a company focused on bifunctional antibodies that
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot